Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases • Leading institutional, corporate, and disease-focused venture capital funds provide financing for greater Philadelphia-based gene therapy startup • Company leveraging novel targeted non-viral gene delivery platform to develop gene therapies for rare and prevalent genetic diseases HATFIELD, Pa., April 20, 2021-- Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases, launches today with $10 million in financing and headquarters in the Philadelphia region’s leading gene therapy epicenter.